Functional Orthosis Versus Cast Immobilization for Partially Unstable Weber B Ankle Fractures

Sponsor
Ostfold Hospital Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT05412693
Collaborator
Alesund Hospital (Other), Sykehuset Innlandet HF (Other)
110
3
2
45
36.7
0.8

Study Details

Study Description

Brief Summary

Stability dictates treatment choice for trans-syndesmotic fibula fractures. Optimal treatment for partially unstable fractures remains a topic of debate. The purpose of this study is to evaluate possible outcome non-inferior of functional orthosis treatment versus cast immobilization for these fractures.

Condition or Disease Intervention/Treatment Phase
  • Device: Functional orthosis
  • Device: Cast immobilization
N/A

Detailed Description

Evidence suggests that Weber B ankle fractures should be treated nonoperatively if the ankle mortise is stable. Stability is maintained if the deltoid ligament is intact, also known as a Weber B/SER2 injury. Functional orthosis treatment is advised for these injuries. Recently, authors have demonstrated that the fractured ankle can be functionally stable even with a partial deltoid ligament injury. Our interpretation of a partial deltoid ligament injury is when weightbearing radiographs indicate stability (no increase in medial clear space), while concomitant gravity stress radiographs indicate instability (due to increase in medial clear space). It is suggested that this is referred to as a Weber B/SER4a injury. Although now considered for nonoperative treatment, partially unstable/SER4a injuries were traditionally treated operatively. Today, the superiority of one method of nonoperative treatment over another for partially unstable/SER4a injuries remains unclear. Some authors advocate cast immobilization while others have shown good outcomes after inconsistently using different orthoses and cast devices. The argument for cast immobilization appears to be a fear of posttraumatic osteoarthritis because of potential recurrent instability. As a result, cast immobilization of partially unstable/SER4a fractures is implemented in reference European guidelines, and thus must be considered the reference treatment. To our knowledge, no study has documented increased prevalence of osteoarthritis associated with functional treatment of partially unstable/SER4a fractures. The use of cast immobilization remains a precautionary principle, but the choice is not so clear cut because cast immobilization comes with an increased risk of joint stiffness and thromboembolic complications. Long-term radiographic and patient-reported outcome data evaluating possible non-inferiority of functional orthosis treatment compared to cast immobilization will assist in guiding future treatment strategies of these common fractures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Masking is not possible during the first 6 weeks of treatment due to the nature of the interventions. Investigators and outcome assessors will be masked for follow-up after 6 weeks.
Primary Purpose:
Treatment
Official Title:
Six Weeks Functional Orthosis Versus Cast Immobilization for Partially Unstable Weber B/SER4a Ankle Fractures - a Multicenter Randomized Non-inferiority Trial
Actual Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Functional orthosis

Use of a functional orthosis device (AirCast Air-Stirrup) for 6 weeks. Weightbearing as tolerated will be allowed in both groups immediately after application of the cast or orthosis.

Device: Functional orthosis
See arm descriptions

Active Comparator: Cast immobilization

Use of a below-the-knee cast circular cast (3M scotch cast) for 6 weeks.

Device: Cast immobilization
See arm descriptions

Outcome Measures

Primary Outcome Measures

  1. Change from 6 weeks Manchester-Oxford Foot and Ankle Questionnaire score at 2 years [6 weeks, 2 years]

    Scale 0-100, lower scores indicate less pain and symptoms.

Secondary Outcome Measures

  1. Change from 6 weeks Olerud Molander Ankle Score at 2 years [6 weeks, 2 years]

    Scale 0-100, higher scores indicate less pain and symptoms.

  2. Numeric rating scale of of patient satisfaction with treatment protocol [6 weeks]

    A 0-10 rating scale for perceived satisfaction with orthosis or cast

  3. Change from baseline tibiotalar congruity at 2 years [Baseline, 2 years]

    Measurement of ankle medial clear space from weightbearing and gravity stress ankle radiographs

  4. Registrations of complications/adverse events [2 years]

    Registration of possible loss of congruence, delayed union, non-union, thromboembolic events

  5. Change from 6 weeks ankle range of motion at 2 years [6 weeks, 2 years]

    Measurement using a goniometer (ad modum Lindsjø)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients:

  • With isolated Weber type B fractures that are deemed stable on weightbearing radiographs (MCS injured ankle - MCS uninjured ankle < 1 mm).

  • With concomitant gravity stress test evaluated as unstable (MCS injured ankle - MCS uninjured ankle < 1 mm)

  • Presenting to one of the participating hospitals, and that are available for stability evaluation within 14 days after injury.

  • 18-80 years of age

  • With pre-injury walking ability without aids.

Exclusion Criteria:
  • Patients:

  • with fracture of the medial malleolus, pre-hospital closed fracture reduction, open fracture, fracture resulting from high-energy trauma or multi-trauma or pathologic fracture.

  • with fracture of the posterior malleolus involving 25% or more of the joint surface or with a step of the intraarticular surface. (non-displaced fractures smaller than 25% can be included)

  • with neuropathies and generalized joint disease such as Rheumatoid Arthritis.

  • that are assumed not compliant (drug use, cognitive- and/or psychiatric disorders).

  • with previous history of ipsilateral ankle fracture.

  • with previous history of ipsilateral major ankle-/foot surgery.

  • who live outside one of the participating hospitals catchment areas (not available for follow-up).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sykehuset Innlandet, Gjøvik Gjøvik Norway
2 Ålesund Hospital Ålesund Norway
3 Østfold Hospital Trust Sarpsborg Østfold Norway 1714

Sponsors and Collaborators

  • Ostfold Hospital Trust
  • Alesund Hospital
  • Sykehuset Innlandet HF

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marius Molund, Head of Foot and Ankle Service, Ostfold Hospital Trust
ClinicalTrials.gov Identifier:
NCT05412693
Other Study ID Numbers:
  • 22/00257-3
First Posted:
Jun 9, 2022
Last Update Posted:
Jun 9, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marius Molund, Head of Foot and Ankle Service, Ostfold Hospital Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 9, 2022